Cencora Inc. ($COR) Stock Forecast: Up 5.1% Today

What is Cencora Inc.?

Cencora Inc. (COR) recently increased its fiscal year 2026 EPS guidance and approved a new $2 billion share repurchase program. The company is a key player in the U.S. healthcare system, specializing in specialty drugs and dealing with regulatory and legal challenges.

Why is Cencora Inc. going up?

COR stock is up 5.1% on May 22, 2026 18:00

• The rise in COR stock value can be linked to the favorable market reaction to Cencora's financial decisions, such as raising its EPS guidance and introducing a substantial share buyback initiative.
• Despite regulatory and legal uncertainties, there is investor confidence in Cencora's steady business model and specialty drug focus, driving up the stock price.
• While the securities fraud investigation by Pomerantz LLP initially caused market uncertainty, the subsequent positive announcements about financial projections and the share repurchase program likely reassured investors and led to the upward trend in stock value.

COR Price Chart

COR Technical Analysis

COR News

Globe Life Inc. $GL Shares Sold by Pzena Investment Management LLC

Pzena Investment Management LLC reduced its stake in Globe Life Inc. by 2.2% in the fourth quarter, though it still holds a significant position. Insiders, including the CEO and an EVP, also sold a substantial number of shares recently. Despite mixed quarterly results, analysts maintain a "Buy" rating for Globe Life with an average target price of $173.22, and the company announced a quarterly dividend of $0.33 per share.

https://www.marketbeat.com/instant-alerts/filing-globe-life-inc-gl-shares-sold-by-pzena-investment-management-llc-2026-05-22/

Cencora Inc. stock (US15135B1017): guidance tweak and extra $2 billion buyback attract fresh attenti

Cencora Inc. has updated its fiscal year 2026 financial outlook, modestly raising its adjusted earnings guidance and authorizing an additional $2 billion for share repurchases. This comes amid an investor rights investigation by Pomerantz LLP. The company, a major pharmaceutical distributor, plays a critical role in the U.S. healthcare system, and its stock benefits from its stable business model and focus on specialty drugs, though it also faces regulatory and legal risks.

https://www.ad-hoc-news.de/boerse/news/ueberblick/cencora-inc-stock-us15135b1017-guidance-tweak-and-extra-2-billion/69400667

Cencora Raises Fiscal 2026 EPS Outlook, Authorizes $2 Billion Share Buyback

Cencora (COR) announced an increase in its long-term financial guidance for fiscal year 2026, raising its diluted earnings per share outlook from a range of $13.15 to $13.50 to a new range of $13.30 to $13.65. The company also authorized a new $2 billion share repurchase program, replacing its previous authorization. These strategic moves were highlighted in their annual Investor Day presentation.

https://www.moomoo.com/news/post/70409572/cencora-raises-fiscal-2026-eps-outlook-authorizes-2-billion-share

Cencora raises FY26 EPS outlook, $2B buyback | COR Stock News

Cencora (NYSE: COR) has updated its fiscal year 2026 financial guidance, increasing its adjusted diluted earnings per share outlook to a range of $17.70 to $17.90 following opportunistic share repurchases in May. Additionally, the company's Board of Directors authorized a new $2.0 billion share repurchase program, reinforcing its commitment to returning value to shareholders. These actions align with Cencora's strategy to optimize market access for pharmaceutical innovators and deliver healthcare products.

https://www.stocktitan.net/news/COR/cencora-announces-updated-fiscal-year-2026-financial-he90ymj3q8r2.html

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

Pomerantz LLP is investigating potential securities fraud claims against Cencora, Inc. (NYSE: COR) on behalf of its investors. This investigation follows a significant drop in Cencora's stock price after the company released its second-quarter 2026 financial results, which missed revenue estimates and reduced full-year guidance due to "manufactured list price reductions." Investors who purchased Cencora securities are encouraged to contact Pomerantz LLP for more information.

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cencora-inc---cor-302779450.html

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Cencora Inc. Price History

05.01.2026 - COR Stock was up 7.6%

• The surge in Cardinal Health's stock price followed strong fiscal second-quarter earnings that exceeded analyst expectations, demonstrating solid financial performance and surpassing revenue projections.
• Investor optimism and the subsequent bullish market movement were fueled by the company's strategic emphasis on specialty drugs and pharmaceutical solutions, along with an upward revision of earnings guidance.
• Cardinal Health's favorable prospects are bolstered by the growing demand for high-margin specialty medications across the industry, in line with the company's growth strategy and financial achievements.

05.01.2026 - COR Stock was up 6.9%

• COR's bullish movement can be attributed to the company's strategic focus on specialty pharmaceuticals and recent acquisitions like OneOncology, which are seen as key drivers for future growth.
• The market reacted positively to COR beating adjusted EPS expectations, despite missing revenue estimates, showcasing investor confidence in the company's growth strategy.
• The overall positive sentiment towards specialty pharmaceuticals, as seen with another company's strong performance and profit forecast boost, likely contributed to the bullish movement in COR's stock.
• COR's emphasis on segment leadership in specialty pharmaceuticals amidst market competition and financing challenges indicates a promising outlook, driving investor optimism and pushing the stock higher.

04.01.2026 - COR Stock was down 8.7%

• Despite surpassing EPS expectations, Cencora (COR) faced a bearish market response due to slightly missing revenue estimates in Q1.
• The stock price declined as the revenue fell short at $85.9 billion, compared to the consensus estimate of $86.02 billion.
• The company's strong position in the U.S. pharmaceutical wholesale market and the successful OneOncology acquisition could have positive long-term effects. However, short-term market sentiment was impacted by the revenue shortfall.
• Concerns about the company's valuation metrics potentially indicating overvaluation may have contributed to the bearish movement, despite the positive surprise in EPS.

04.01.2026 - COR Stock was down 9.2%

• Cencora (COR) posted remarkable first fiscal quarter earnings, outperforming expectations on adjusted EPS and displaying revenue growth compared to the previous year.
• The stock's decline might be linked to a slight shortfall in revenue compared to Wall Street estimates, despite the positive earnings results.
• The completion of the OneOncology acquisition and the revised guidance for fiscal 2026 signal favorable growth prospects for Cencora, but concerns regarding overvaluation could have influenced the market's reaction.
• Overall, the market's bearish response may stem from a combination of revenue missing estimates, worries about overvaluation, and profit-taking after the stock's recent performance.

22.04.2026 - COR Stock was up 5.1%

• The rise in COR stock value can be linked to the favorable market reaction to Cencora's financial decisions, such as raising its EPS guidance and introducing a substantial share buyback initiative.
• Despite regulatory and legal uncertainties, there is investor confidence in Cencora's steady business model and specialty drug focus, driving up the stock price.
• While the securities fraud investigation by Pomerantz LLP initially caused market uncertainty, the subsequent positive announcements about financial projections and the share repurchase program likely reassured investors and led to the upward trend in stock value.

17.02.2026 - COR Stock was down 5.0%

• The CFO's retirement at Cencora Inc may have triggered uncertainty among investors, resulting in a bearish movement in the stock.
• Despite the retirement news, the company's decision to uphold its fiscal year 2026 guidance suggests stability and confidence in its future performance.
• Investor caution during the transition period and the search for a successor may be contributing to the stock's downward pressure.
• Market sentiment towards Cencora Inc appears mixed, weighing the company's financial health and growth prospects against the CFO transition uncertainty.

17.02.2026 - COR Stock was down 5.0%

• The retirement announcement of the Chief Financial Officer may have caused uncertainty among investors, leading to a bearish movement in the stock.
• The significant reduction in stock holdings by multiple management entities and insiders selling shares worth millions could have signaled a lack of confidence in the company's future performance.
• Despite holding steady amid healthcare distribution resilience and positive market outlook, the downward revision in stock evaluation and increased selling activities might have contributed to the bearish trend in COR's stock price.
• The combination of insider selling, reduction in institutional stakes, and mixed market indicators could have created a negative sentiment around COR, leading to the bearish movement observed today.

06.04.2026 - COR Stock was down 17.0%

• COR's second-quarter earnings fell short of analyst projections, with adjusted EPS at $4.75 compared to the expected $4.82 per share.
• Despite the earnings miss, COR revised its full-year adjusted EPS guidance upwards, potentially signaling confidence in its future performance.
• The market responded negatively to the earnings report, leading to a 2% decline in COR's share price during pre-market trading.
• While the recent OneOncology acquisition significantly benefitted the company's performance, concerns regarding balance-sheet leverage and thin margins likely contributed to the stock price decline.

12.01.2026 - COR Stock was down 2.4%

• Several factors may explain the bearish movement in COR's stock price today:
• The reduction in stake by Atria Investments Inc following positive earnings and dividend news may have raised concerns about the company's future growth prospects.
• The issuance of $3 billion in senior unsecured notes could have led to worries about increased debt levels and potential shareholder value dilution.
• Market sentiment toward healthcare companies, exemplified by Cosmos Health's pivot to Bitcoin, may have negatively impacted COR's stock price.
• The forthcoming ex-dividend date for COR may have prompted some investors to liquidate their holdings, contributing to the stock's bearish trend.

08.04.2026 - COR Stock was up 5.1%

• Cencora Inc. (COR) shares increased by 1.16% to $255.66, demonstrating a positive trend.
• The company's impressive second-quarter results included revenue of $78.36 billion and diluted EPS of $8.4, influencing the market positively.
• Although the company did not meet analysts' expectations for earnings per share and revenue, growth was fueled by volume increases in healthcare segments, specialty sales, recent acquisitions, and high demand for GLP-1 therapies.
• Cencora's stock was undervalued, according to Simply Wall St, and investors may have been attracted by this, along with anticipated enhancements in supply chain efficiency and transparency, contributing to the market uptrend.

07.04.2026 - COR Stock was down 5.4%

• Cencora's second-quarter earnings and sales missing analyst consensus led to a bearish trend in the stock.
• Despite an increase in fiscal 2026 adjusted earnings guidance, lowering sales guidance raised investors' concerns.
• Technical analysis indicating weakening momentum and a weak profile across value, growth, and momentum have added to the downward pressure on Cencora's stock.
• The market's response to the guidance cut and Cencora's stock hitting a new 52-week low suggest a less hopeful outlook for the company's future performance, contributing to the bearish movement seen today.

06.04.2026 - COR Stock was down 17.1%

• COR stock experienced a strong bearish movement today, dropping 17.6%.
• The drop was primarily driven by the company's fiscal Q2 results missing revenue expectations and highlighting near-term headwinds, such as concerns over demand mix, customer-related headwinds, and pricing dynamics within its U.S. Healthcare Solutions segment.
• Despite the earnings miss, COR raised its full-year adjusted EPS guidance and announced plans for share buybacks, showing confidence in its future performance but failing to reassure investors in the short term.
• The market reaction suggests that investors are particularly sensitive to revenue misses and operational challenges, leading to a significant sell-off in COR stock.